---
schema_version: "secwatch.filing_event.v1"
accession: "0001438533-24-000019"
form_type: "8-K"
ticker: "TVTX"
cik: "0001438533"
company_name: "Travere Therapeutics, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T21:55:07.095304+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Travere Q1: FILSPARI sales $19.8M; FDA Priority Review for full approval by Sept 5

## Summary
- Net product sales $40.0M (Q1 2024), up from $24.2M YoY, driven by FILSPARI launch.
- FILSPARI net sales $19.8M; 511 new PSFs in Q1, total 1,963 since launch.
- FDA granted Priority Review for sNDA to convert accelerated approval to full approval for IgAN; PDUFA Sept 5, 2024.
- Net loss $136.1M ($1.76/share) vs $86.3M loss in Q1 2023, including $65M IPR&D milestone for pegtibatinase.
- Cash, equivalents, and securities $441.0M as of March 31, 2024.

## SEC filing metadata
- accession: 0001438533-24-000019
- form_type: 8-K
- ticker: TVTX
- cik: 0001438533
- company_name: Travere Therapeutics, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/tvtx-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001438533-24-000019
- JSON: https://secwatch.observer/filing/0001438533-24-000019.json
- Plain text: https://secwatch.observer/filing/0001438533-24-000019.txt

## Key facts
- Earnings Releases
  Travere Therapeutics, Inc. reported the first quarter of 2024 results: revenue $40.0 million, net income $136.1 million, or $1.76 per basic share, EPS $1.76 per basic share.
  - Period: the first quarter of 2024
  - Revenue: $40.0 million
  - Net income: $136.1 million, or $1.76 per basic share
  - EPS: $1.76 per basic share
  - Result: reported results
  source text: Net product sales for the first quarter of 2024 were $40.0 million, compared to $24.2 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1438533/000143853324000019/0001438533-24-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.